Based on these findings and in vitro drug trials, some scholars have speculated that anti-PD-1/PD-L1 therapy may be a promising option for NSCLC patients with upregulated PD-L1 carrying the EML4-ALK fusion gene (53). Here, EML4 is linked to non-small cell lung carcinoma.